11 Best Performing Long Term Stocks According to Analysts

9. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

5-year Revenue Growth Rate: 20.98%

Year-To-Date Performance: 30.87%

Number of Hedge Fund Holders: 33

Analysts Upside Potential: 26.95%

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is one of the Best Performing Long Term Stocks According to Analysts. On September 12, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced interim results from its LOTUS study on DAYBUE for Rett syndrome patients. The study included 227 patients aged 1 to 60 years across the United States treated with DAYBUE under routine care for up to 12 months.

The results reported behavioral improvements in 71% to 90% of patients, assessed by a questionnaire developed by the company. The most notable improvements were seen in nonverbal communication, alertness, and social interaction. Moreover, quality of life also showed modest gains in the subset assessed at 12 months.

Management noted that the median dose reached about 80% of the target FDA-approved dose after 10 weeks. Limitations of this real-world study include no placebo arm, reliance on caregiver reports, and incomplete data at later timepoints. The results support that long-term DAYBUE treatment can improve Rett syndrome symptoms and provide new insights on managing GI side effects in clinical practice.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical company focused on developing and marketing innovative therapies for central nervous system disorders and rare diseases.